Dr. Aharon Schwartz served in various roles of increasing responsibility at Teva Pharmaceuticals from 1975 through 2011, most recently as Vice President, Head of Teva Innovative Ventures - TIV, which he held from 2008 to 2011. From 2001 until 2008, Dr. Schwartz held the position of Vice President, Strategic Affairs. Prior to this position, from 1992 to 2001, Dr. Schwartz created and led the Copaxone division of Teva. From 1985 to 1992 Dr. Schwartz served as the head of the pharmaceutical division of Teva in Israel. Dr. Schwartz is currently Chairman of the Board for Biolinerx . He is also a member of the Board of Directors for Protalix and Opharex . Dr. Schwartz has a Ph.D. in organic chemistry from the Weizmann Institute, a M.Sc. in organic chemistry from the Technion School, a B.Sc. in chemistry and physics from the Hebrew University of Jerusalem, and a second Ph.D. from the Hebrew University of Jerusalem in the history and philosophy of science.